Welcome to our dedicated page for Thermo Fishr Sci SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Thermo Fisher Scientific Inc. (NYSE: TMO) files a wide range of documents with the U.S. Securities and Exchange Commission, and this page aggregates those SEC filings for investors tracking TMO. The company’s common stock and multiple series of senior notes are listed on the New York Stock Exchange, and its filings describe the terms, rankings and covenants of these securities, as well as material events affecting the business.
Recent Form 8‑K filings illustrate the types of information Thermo Fisher discloses. Several 8‑Ks detail public offerings of senior notes in U.S. dollars and euros, including maturities, interest payment schedules, redemption provisions, change‑of‑control protections and the use of proceeds for general corporate purposes such as acquisitions, debt repayment or refinancing, working capital, capital expenditures or equity repurchases. Other 8‑Ks report the completion of the acquisition of Solventum Corporation’s purification and filtration business and the signing of a definitive agreement to acquire Clario Holdings, Inc.
Thermo Fisher also uses 8‑K filings to communicate quarterly financial results, leadership transitions and organizational changes. For example, filings describe announcements of financial results for specific fiscal quarters, the planned retirement of the Senior Vice President and Chief Financial Officer and the appointment of a successor, and updates to the organizational structure and leadership team, including changes in executive roles.
On Stock Titan’s SEC filings page for TMO, users can access these current reports alongside other registered securities information, and benefit from AI‑powered summaries that explain key terms, highlight significant covenants, and clarify how new debt offerings, acquisitions, leadership changes or other material events may affect Thermo Fisher Scientific’s capital structure and corporate profile.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer sold 1,607 shares of common stock in an open-market transaction. The sale occurred at a price of $499.40 per share, and followed a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025.
After this transaction, Shafer directly holds 20,949.9546 Thermo Fisher Scientific shares. Because the trade was executed under a Rule 10b5-1 plan, its timing reflects a preset schedule rather than a discretionary market-timing decision.
Thermo Fisher Scientific Inc. senior vice president and CFO James Meyer filed an initial ownership statement reporting his equity stake in the company. The filing shows direct ownership of 5,841.4637 shares of common stock and an additional 50.03 shares held indirectly through a 401(k) plan.
He also reports multiple stock option awards on Thermo Fisher common stock with exercise prices ranging from 430.7300 to 635.1000 per share and expiration dates between 2028 and 2035. Individual grants include, for example, 6,851 underlying shares at an exercise price of 513.6800 and 3,598 underlying shares at an exercise price of 430.7300, reflecting substantial unexercised option-based exposure.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 4,000 shares of common stock and reported related trades in Thermo Fisher Scientific Inc. stock. The option exercise, at an exercise price of $0.00 per share, converted into 4,000 shares of common stock.
On the same date, he sold 4,000 shares of common stock in a series of open-market transactions at prices ranging from $503.66 to $519.74, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 125,360.358 shares of common stock.
Additional shares are held indirectly by the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares) and the MNC 2020 Irrevocable Trust (5,000 shares, all as of the reported date), with Casper disclaiming beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.
Thermo Fisher Scientific Inc. Chairman & CEO Marc N. Casper reported option exercises and related share sales in company stock. On March 3 and 4, 2026, he exercised stock options for a total of 10,000 shares of Common Stock at a reported exercise price of $309.63 per share in multiple transactions coded as derivative exercises.
Over the same two days, Casper sold 10,000 shares of Common Stock in a series of open-market transactions, with prices reported around $495.29–$517.05 per share as weighted-average prices across multiple trades. The transactions were effected under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 123,925.358 shares of Common Stock and 44,550 stock options. Additional shares are held indirectly through the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except for any pecuniary interest.
TMO files a Rule 144 notice reporting a proposed cash sale of 4,000 common shares on 03/05/2026.
The filing lists the securities as options granted on 02/25/2020 and identifies the sale method as cash. The excerpt also shows prior reported sales by Marc N. Casper: 5,000 shares on 03/03/2026 and 5,000 shares on 03/04/2026.
Marc Casper reported the sale of 5,000 common shares of TMO. The filing shows a sale dated 03/03/2026 with aggregate proceeds of $2,507,550.00 and a separate planned sale entry of 5,000 shares on 03/04/2026 tied to an option granted 02/25/2020.
Brokerage details list Fidelity Brokerage Services LLC and the transaction type is listed as Cash. The filing is a Form 144 disclosure of insider sales under the issuer symbol TMO.
Filer submitted a Form 144 notice to sell Common stock of the issuer (symbol TMO). The filing lists multiple restricted stock vesting lots and share counts by vesting date, including 980 shares vesting 02/23/2024, 955 shares vesting 02/28/2024, and other lots of 776, 705, 577, 434, 389, 233, 123, and 52 shares on various dates. The listed broker is Fidelity Brokerage Services LLC.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported two tax-withholding dispositions of common stock on February 28, 2026. He delivered 3,473.759 shares and 1,211.168 shares at $521.11 per share to cover tax liabilities, rather than executing open-market sales. Following these dispositions, he directly held 123,925.358 common shares. Additional common shares are held indirectly by the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except to any pecuniary interest.